China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma

Stock News

08/04

CARSGEN-B (02171) has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. This clearance is for treating patients with relapsed/refractory multiple myeloma (R/R MM).

The results from CT0596's Investigator-Initiated Trial (IIT) were previously presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeting universal CAR-T cell therapy developed usingCARSGEN-B's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or plasma cell leukemia (PCL).

The therapy has shown an initial favorable safety profile and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1151736677"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151736677\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151736677?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151736677","market":"sh","top_or_hot":-1,"title":"China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma","media":"Stock News","content":"<p><b>CARSGEN-B (02171)</b> has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. This clearance is for treating patients with relapsed/refractory multiple myeloma (R/R MM).<br><br>The results from CT0596's Investigator-Initiated Trial (IIT) were previously presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeting universal CAR-T cell therapy developed using<b>CARSGEN-B</b>'s proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or plasma cell leukemia (PCL).<br><br>The therapy has shown an initial favorable safety profile and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina's Nod Granted to CARSGEN-B's BCMA-Targeting Universal CAR-T for Hard-to-Treat Myeloma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-04 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>CARSGEN-B (02171)</b> has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. This clearance is for treating patients with relapsed/refractory multiple myeloma (R/R MM).<br><br>The results from CT0596's Investigator-Initiated Trial (IIT) were previously presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeting universal CAR-T cell therapy developed using<b>CARSGEN-B</b>'s proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or plasma cell leukemia (PCL).<br><br>The therapy has shown an initial favorable safety profile and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1151736677","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151736677","pubTimestamp":1785802452,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B","BK1587":"次新股","BK1161":"生物科技","BK1574":"生物医药B类股","BK1585":"昨日强势股","IND":"Xtrackers Nifty 500 India ETF"},"translate_title":"中国批准CARSGEN-B针对BCMA的通用CAR-T治疗难治性骨髓瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1,"IND":1},"content_text":"CARSGEN-B (02171) has announced that its universal CAR-T cell product, CT0596, which targets BCMA, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. This clearance is for treating patients with relapsed/refractory multiple myeloma (R/R MM).The results from CT0596's Investigator-Initiated Trial (IIT) were previously presented as a poster at the 2026 European Hematology Association (EHA) Annual Congress. CT0596 is a BCMA-targeting universal CAR-T cell therapy developed usingCARSGEN-B's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or plasma cell leukemia (PCL).The therapy has shown an initial favorable safety profile and encouraging efficacy signals. The company also plans to further explore its potential in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}